glp-1 grey market Agonists Weight Loss Drugs Report, 2025-2030 Market Overview: GLP-1 Agonists and

Forte N, Marfella B, Nicois A, Palomba L, Paris D, Motta A et al (2024) The short-chain fatty acid acetate modulates orexin/hypocretin neurons: a novel mechanism in gut-brain axis regulation of energy homeostasis and feeding

However, growing awareness of the potential gallbladder risks associated with GLP-1 therapy has prompted clinicians to take a closer look at hepatobiliary safety

Additional reports have linked the substance to serious adverse health effects, including systemic toxicity and muscle damage

Myth: If the medication is clear, it must be safe. Fact: While cloudiness is a sign of spoilage, a clear solution can still be ineffective if the proteins have denatured due to heat

& Licinio, J

It may interact with serotonergic medications (SSRIs/MAOIs) and should be avoided by individuals with G6PD deficiency